May 2018, VOLUME 141 / ISSUE 5
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial
Lisa M. Dunkle, Ruvim Izikson, Peter A. Patriarca, Karen L. Goldenthal, Manon Cox, John J. Treanor
Pediatrics May 2018, 141 (5) e20173021; DOI: 10.1542/peds.2017-3021
Recombinant HA provided better protection than the inactivated influenza vaccine in adults ≥50 years old but lower immunogenicity in children <5 years old. In subjects 6 to 17 years old, immunogenicity was comparable.